Joseph K Belanoff MD
Chief Executive Officer, President, and Director
Dr Belanoff is the co-founder of Corcept Therapeutics and has served as a member of the Board and as the Chief Executive Officer since 1999. In 2013, he was also appointed President. Dr Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. Dr Belanoff received his BA from Amherst College and his MD from Columbia University’s College of Physicians & Surgeons.
Robert S Fishman MD
Chief Medical Officer
Dr Fishman joined Corcept as Chief Medical Officer in September 2015. He brings to the company more than 22 years of product development experience, most recently at InterMune, Inc., where from 2012 to 2015, he was Senior Vice President of Clinical Development and led the final pivotal trial of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. From 2007 to 2012, he served as Vice President of Clinical Development at Alexza Pharmaceuticals, where he led the clinical development of inhaled loxapine (Adasuve®) for the treatment of agitation in patients with schizophrenia or bipolar disorder. Before that, Dr Fishman held positions of increasing responsibility at Heartport, Aerogen, and Anthera Pharmaceuticals. He trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford pulmonary medicine faculty. He earned an AB from Harvard University and an MD from Stanford University School of Medicine.
Hazel Hunt PhD
Senior Vice President, Research
Dr Hunt joined Corcept in 2011, bringing with her more than 23 years of experience in the pharmaceutical and biotechnology industries. From 2002 to 2011, she was Director of Chemistry and Operations at Argenta, where she worked closely with Corcept and played an integral role in the discovery of Corcept’s portfolio of next-generation selective GR antagonists. From 1994 to 2002, she worked for Celltech, initially as a Group Leader in Medicinal Chemistry and ultimately as Section Leader, Project Chemistry. From 1992 to 1994, she served as a Research Fellow at The Centre for Drug Design and Development. Before that Dr Hunt worked at Glaxo Group Research as a Senior Chemist in Medicinal Chemistry. Dr Hunt received a first-class honors degree in chemistry from the Australian National University and a PhD in synthetic organic chemistry from the University of Southampton, UK. She also carried out postdoctoral work at Oxford University and the University of California at Irvine.
Senior Vice President, Commercial
Mr Maduck was named Corcept’s Senior Vice President, Commercial, in 2016. Prior to that, he was the company’s Vice President, Sales & Marketing. Mr Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning, and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr Maduck earned an AB from Dartmouth College, a BE in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.
Chief Financial Officer
Mr Robb joined us as Chief Financial Officer in September 2011. Mr Robb has more than 25 years of experience in executive management, operations and finance. From April 2005 through August 2011, Mr Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a fitness equipment and training company with operations in the United States, Europe, and Asia. From 2003 to 2005, Mr Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc., from 1996 to 1998. From 1992 to 1996, Mr Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr Robb earned a BA in English and Political Philosophy from Yale and a JD from Harvard Law School, where he was a member of the Harvard Law Review.